



## Disclosure of total number of voting rights and number of shares in the capital as of December 31, 2025

Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations.

Total number of shares	<b>36,751,358</b>
Number of real voting rights* (excluding treasury shares**)	<b>36,690,400</b>
Theoretical number of voting rights* (including treasury shares**)	<b>36,728,158</b>

(\*) Class E preference shares are non-voting

(\*\*) pursuant to article 223-11 of the AMF's General Regulations



**About Median Technologies:** Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit [www.mediantechologies.com](http://www.mediantechologies.com).

### Contacts

#### Median Technologies

Emmanuelle Leygues  
VP, Corporate Marketing & Financial Communications  
+33 6 10 93 58 88  
[emmanuelle.leygues@mediantechologies.com](mailto:emmanuelle.leygues@mediantechologies.com)

#### Press – Ulysse Communication

Bruno Arabian  
+33 6 87 88 47 26  
[barabian@ulysse-communication.com](mailto:barabian@ulysse-communication.com)  
Nicolas Entz  
+33 6 33 67 31 54  
[nentz@ulysse-communication.com](mailto:nentz@ulysse-communication.com)

#### Investors - ACTIFIN

Ghislaine Gasparetto  
+33 6 85 36 76 81  
[ghislaine.gasparetto@seitosei-actifin.com](mailto:ghislaine.gasparetto@seitosei-actifin.com)